Increased prescribing of proton pump inhibitors in ambulatory care over the years 2005-2013;Steigende Verordnungszahlen von Protonenpumpenhemmern im ambulant-ärztlichen Bereich über dieA Jahre 2005-2013

Zeitschrift fur Gastroenterologie

Volumn 53, Issue 2, 2015, Pages 95-100

  Hoffmann, F ^a   Glaeske, G ^a   Schmiemann, G ^a  

^a UNIVERSITY OF BREMEN   (Germany)

Author keywords

gastrointestinal bleeding; Helicobacter pylori; reflux oesophagitis

Indexed keywords

PROTON PUMP INHIBITOR;

AMBULATORY CARE; ARTICLE; DRUG UTILIZATION; FEMALE; GENERAL PRACTITIONER; GERMANY; HUMAN; MALE; PRESCRIPTION; PREVALENCE; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHILD; CLINICAL PRACTICE; DRUG USE; GASTROESOPHAGEAL REFLUX; INAPPROPRIATE PRESCRIBING; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; SEX RATIO; STATISTICS AND NUMERICAL DATA; TRENDS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AMBULATORY CARE; CHILD; CHILD, PRESCHOOL; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; FEMALE; GASTROESOPHAGEAL REFLUX; GERMANY; HUMANS; INAPPROPRIATE PRESCRIBING; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; PROTON PUMP INHIBITORS; SEX DISTRIBUTION; YOUNG ADULT;

EID: 84923372288     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0034-1384973     Document Type: Article

References (39)

1. Katz P. O., Gerson L. B., Vela M. F. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol: 2013; 108 308 328; quiz 329
2. Fischbach W., Malfertheiner P., Hoffmann J. C. et al. S3-guideline Helicobacter pylori and gastroduodenal ulcer disease Z Gastroenterol: 2009; 47 68 102
3. Lanza F. L., Chan F. KL, Quigley E. MM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol: 2009; 104 728 738
4. Corleto V. D., Festa S., Di Giulio E. et al. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes: 2014; 21 3 8
5. Haag S. Long-term use of proton pump inhibitors - really harmless? Dtsch Med Wochenschr: 2013; 138 2319 2321
6. Piezzi V., Kullak-Ublick G. A., Glisenti P. A 78-year-old female patient with dizziness, apraxia and seizure under proton pump inhibitor therapy. Internist (Berl): 2014; 55 199 205
7. Florentin M., Elisaf M. S. Proton pump inhibitor-induced hypomagnesemia: A new challenge. World J Nephrol: 2012; 1 151 154
8. Khalili H., Huang E. S., Jacobson B. C. et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ: 2012; 344 e372
9. Reimer C., Sondergaard B., Hilsted L. et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology: 2009; 137 80 87, 87.e1
10. Lodrup A. B., Reimer C., Bytzer P. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. Scand J Gastroenterol: 2013; 48 515 522
11. Sarkar M., Hennessy S., Yang Y. X. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med: 2008; 149 391 398
12. Herzig S. J., Howell M. D., Ngo L. H. et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA: 2009; 301 2120 2128
13. Filion K. B., Chateau D., Targownik L. E. et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut: 2014; 63 552 558
14. Freedberg D. E., Abrams J. A. Clostridium difficile infection in the community: are proton pump inhibitors to blame? World J Gastroenterol: 2013; 19 6710 6713
15. Tleyjeh I. M., Bin Abdulhak A. A., Riaz M. et al. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One: 2012; 7 e50836
16. Hoffmann F., Schmiemann G. Protonenpumpenhemmer - grundsätzlich zu viel oder manchmal auch zu wenig? In: Glaeske G., Schicktanz C. (eds): BARMER GEK Arzneimittelreport. Siegburg Asgard: 2014; 128 147
17. Canadian Institute for Health Information Proton Pump Inhibitor UseA in Seniors: An Analysis Focusing on Drug Claims, 2001 to 2008. https://secure.cihi.ca/free-products/PPI-aib-en.pdf (date accessed: 17.04.2014)
18. Cai S., García Rodríguez L. A., Massó-González E. L. et al. Uncomplicated peptic ulcer in the UK: trends from 1997 to 2005. Aliment Pharmacol Ther: 2009; 30 1039 1048
19. De Bruyne P., Christiaens T., Stichele R. V. et al. Changes in prescription patterns of Acid-suppressant medications by belgian pediatricians: analysis of the national database, [1997-2009]. J Pediatr Gastroenterol Nutr: 2014; 58 222 227
20. Mazer-Amirshahi M., Mullins P. M., van den Anker J. et al. Rising rates of proton pump inhibitor prescribing in US emergency departments. Am J Emerg Med: 2014; 32 618 622
21. Forgacs I., Loganayagam A. Overprescribing proton pump inhibitors. BMJ: 2008; 336 2 3
22. Ahrens D., Behrens G., Himmel W. et al. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract: 2012; 66 767 773
23. Schwabe U., Paffrath D. Arzneiverordnungs-Report 2013. Berlin, Heidelberg Springer: 2013
24. Schwabe U., Paffrath D. Arzneiverordnungs-Report 1994. Stuttgart, Jena Fischer: 1994
25. Hoffmann F., Glaeske G., Petermann F. et al. Outpatient treatment in German adolescents with depression: an analysis of nationwide health insurance data. Pharmacoepidemiol Drug Saf: 2012; 21 972 979
26. Schulze J., van den Bussche H., Glaeske G. et al. Impact of safety warnings on antipsychotic prescriptions in dementia: Nothing has changed but the years and the substances. Eur Neuropsychopharmacol: 2013; 23 1034 1042
27. Friedenberg F. K., Hanlon A., Vanar V. et al. Trends in gastroesophageal reflux disease as measured by the National Ambulatory Medical Care Survey. Dig Dis Sci: 2010; 55 1911 1917
28. El-Serag H. B., Sweet S., Winchester C. C. et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut: 2014; 63 871 880
29. Van Boxel O. S., Hagenaars M. P., Smout A. JPM et al. Socio-demographic factors influence chronic proton pump inhibitor use by a large population in the Netherlands. Aliment Pharmacol Ther: 2009; 29 571 579
30. De Souto Barreto P., Lapeyre-Mestre M., Mathieu C. et al. Prevalence and associations of the use of proton-pump inhibitors in nursing homes: a cross-sectional study. J Am Med Dir Assoc: 2013; 14 265 269
31. Nocon M., Keil T., Willich S. N. Prevalence and sociodemographics of reflux symptoms in Germany - results from a national survey. Aliment Pharmacol Ther: 2006; 23 1601 1605
32. Kim K-M, Cho Y. K., Bae S. J. et al. Prevalence of gastroesophageal reflux disease in Korea and associated health-care utilization: a national population-based study. J Gastroenterol Hepatol: 2012; 27 741 745
33. Sobieraj D. M., Coleman S. M., Coleman C. I. US prevalence of upper gastrointestinal symptoms: a systematic literature review. Am J Manag Care: 2011; 17 e449 e458
34. Lin K. J., García Rodríguez L. A., Hernández-Díaz S. Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates? Pharmacoepidemiol Drug Saf: 2011; 20 718 28
35. Ahrens D., Chenot J. F., Behrens G. et al. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol: 2010; 66 1265 1271
36. Pham C. QD, Regal R. E., Bostwick T. R. et al. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother: 2006; 40 1261 1266
37. Hoffmann F., Icks A. Diabetes epidemic in Germany? A critical look at health insurance data sources. Exp Clin Endocrinol diabetes: 2012; 120 410 415
38. Hoffmann F., Icks A. Structural differences between health insurance funds and their impact on health services research: results from the Bertelsmann Health-Care Monitor. Gesundheitswesen: 2012; 74 291 297
39. Hoffmann F., Bachmann C. J. Differences in sociodemographic characteristics, health, and health service use of children and adolescents according to their health insurance funds. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz: 2014; 57 455 463